Controlled attenuation parameter

Biomarker6 papers3 findings

Humans5

Interventions

2

Bariatric surgery

downin humans1Very low certainty

1 study

Bariatric surgery decreases controlled attenuation parameter in humans (-83.7 ± 10.0 dB/m).
Humansin obesity with MASLD72 weeksn = 32
Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD · The Journal of clinical endocrinology and metabolism · 27 Aug 2026

Bariatric surgery →

Semaglutide

downin humans1Very low certainty

1 study

Semaglutide decreases controlled attenuation parameter in humans (-46.0 ± 14.0 dB/m).
Humansin obesity with MASLD72 weeksn = 30
Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD · The Journal of clinical endocrinology and metabolism · 27 Aug 2026

Semaglutide →

Associations

1

Depersonalisation

upin humans1

1 study

Depersonalisation is associated with controlled attenuation parameter in humans (β = 2.43 dB/m per point; 95% CI 0.51 to 4.35; P = 0.014).
Humansadjusted for age, sex, body mass index, and glycated haemoglobinn = 106
Burnout, resilience, and cardiometabolic phenotype in an academic medical faculty: an integrated cross-sectional assessment from the United Arab Emirates · Frontiers in endocrinology · 17 Aug 2026

Latest

10

Frontiers in Digital HealthHumans1 h

Development of a machine learning model to identify individuals with VCTE-derived at-risk MASH in a Spanish Mediterranean region

Clinical and Experimental HepatologyHumans11 Sep

Biological age acceleration and extrahepatic multimorbidity in U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cross-sectional study

Metabolic dysfunction-associated steatotic liver disease

Frontiers in EndocrinologyHumans1 Sep

Burnout, resilience, and cardiometabolic phenotype in an academic medical faculty: an integrated cross-sectional assessment from the United Arab Emirates

Clinical Nutrition ESPENHumans31 Aug

Waist-to-height ratio reveals hidden metabolic risk in lean individuals with MASLD

Waist-to-height ratio

Frontiers in GastroenterologyReview28 Aug

The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis

Journal of Gastroenterology and HepatologyHumans28 Aug

Comparable Predictive Performance of Non-VCTE-Based Machine Learning Model for HBV-Infected Hepatocellular Carcinoma Risk

Hepatocellular carcinoma

The Journal of Clinical Endocrinology and MetabolismHumans27 Aug

Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD

ADA Scientific Sessions 2026 AbstractHumans6 Jun

Waist-to-Height Ratio Outperforms BMI in Identifying Hepatic Steatosis and Fibrosis in U.S. Adults

ADA Scientific Sessions 2026 AbstractHuman trial5 Jun

Longitudinal Dynamics of Cardiometabolic Parameters in a MASH Population Stratified by Baseline Glycemia and Treated with Semaglutide: Post Hoc Insights from the ESSENCE Trial Part 1

AHA Scientific Sessions 2025 AbstractHumans3 Nov

Hepatic Steatosis and Subsequent Fibrosis Are Strongly Associated with Cardiometabolic Risk Clustering in Adults in the United States